SequelSEC

SUPERNUS PHARMACEUTICALS, INC. SUPN

Pharmaceutical Preparations · CIK 0001356576 · Fiscal year ends 1231

Revenue
$718.95M
Fiscal year ended 2025-12-31
Operating income
-$62.28M
Fiscal year ended 2025-12-31
Free cash flow
$45.99M
Fiscal year ended 2025-12-31

SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported revenue of $718.95M and net income of -$38.55M for the fiscal year ended 2025-12-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from SUPERNUS PHARMACEUTICALS, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

SUPERNUS PHARMACEUTICALS, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$718.95M$661.82M$607.52M$667.24M$579.78M$520.40M$392.76M$408.90M$302.24M$215.00M
Cost of revenue$74.56M$77.91M$83.78M$87.22MUnavailable$52.46M$16.66M$15.36M$15.22M$11.99M
Gross profit$644.39M$583.91M$523.74M$580.02MUnavailableUnavailableUnavailable$393.54M$287.02M$203.02M
Operating income-$62.28M$81.67M-$5.27M$46.12M$86.03M$173.70M$148.57M$144.44M$99.54M$54.22M
Net income-$38.55M$73.86M$1.32M$60.71M$53.42M$126.95M$113.06M$110.99M$57.28M$91.22M
Research & development$106.24M$108.80M$91.59M$74.55M$90.47M$75.96M$69.10M$89.21M$49.58M$42.79M
Weighted-average diluted sharesshares 56.45Mshares 55.96Mshares 55.51Mshares 61.68Mshares 54.36Mshares 53.69Mshares 53.82Mshares 54.10Mshares 53.30Mshares 51.71M
Pretax income-$49.03M$97.87M$2.77M$60.74M$73.18M$168.65M$147.49M$140.18M$100.62M$50.37M
Income tax expense-$10.48M$24.00M$1.45M$32.00K$19.75M$41.70M$34.43M$29.18M$43.33M-$40.85M
Diluted EPS$-0.68$1.32$0.02$1.04$0.98$2.36$2.10$2.05$1.08$1.76
Selling, general & administrative$485.56M$321.58M$336.36M$377.22M$304.76M$200.68M$153.25M$154.70M$137.90M$106.01M
General & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

SUPERNUS PHARMACEUTICALS, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Cash & equivalents$128.45M$69.33M$75.05M$93.12M$203.43M$288.64M$181.38M$192.25M$100.30M$66.40M
Total assets$1.45B$1.37B$1.28B$1.70B$1.69B$1.50B$1.16B$977.81M$424.46M$309.57M
Current assets$644.18M$686.07M$493.11M$734.15M$601.59M$630.42M$472.64M$493.49M$228.45M$151.40M
Total liabilities$390.93M$332.34M$356.16M$816.30M$873.30M$759.24M$564.85M$524.79M$156.98M$117.81M
Current liabilities$338.17M$292.40M$290.20M$687.96M$315.38M$245.11M$160.59M$161.35M$123.00M$80.74M
Total equity incl. NCI$1.06B$1.04B$921.52M$886.20M$815.85M$744.86M$595.43M$453.02M$267.48M$191.76M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$112.48M$54.29M$77.41M$91.54M$85.96M$48.32M$26.63M$25.66M$16.30M$16.80M
Accounts receivable$187.80M$142.08M$144.16M$165.50M$148.93M$140.88M$87.33M$102.92M$65.59M$41.53M
Goodwill$124.88M$117.02M$117.02M$117.02M$117.52M$77.91M$0UnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailable$379.25MUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$2.68M$4.59M$1.96M$10.54M$9.33M$6.15M$10.14M$3.20M$6.84M$8.06M

Cash flow

SUPERNUS PHARMACEUTICALS, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Operating cash flow$47.33M$171.95M$111.08M$116.83M$127.13M$138.40M$143.13M$128.99M$114.64M$66.81M
Capital expenditures$1.34M$725.00K$551.00K$412.00KUnavailable$3.45M$2.74M$844.00K$2.03M$1.60M
Investing cash flow$4.11M-$189.87M$268.73M-$216.66M-$81.91M-$34.70M-$157.92M-$413.48M-$86.42M-$35.96M
Financing cash flow$9.13M$12.19M-$397.88M-$10.48M-$130.42M$3.56M$3.93M$376.44M$5.68M$2.05M
Net change in cash$60.57M-$5.72M-$18.07M-$110.31M-$85.21M$107.26M-$10.87M$91.94M$33.91M$32.90M
Stock-based compensation$33.05M$27.76M$26.76M$17.57M$17.91M$16.56M$14.85M$11.29M$8.43M$5.93M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$91.56M$80.41M$84.86M$85.54M$32.60M$18.14M$6.66M$7.06M$8.13M$2.40M

Derived

SUPERNUS PHARMACEUTICALS, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Free cash flow$45.99M$171.23M$110.53M$116.41MUnavailableUnavailableUnavailable$128.14M$112.61M$65.21M
Gross margin89.6%88.2%86.2%86.9%UnavailableUnavailableUnavailable96.2%95.0%94.4%
Operating margin-8.7%12.3%-0.9%6.9%14.8%33.4%37.8%35.3%32.9%25.2%
FCF margin6.4%25.9%18.2%17.4%UnavailableUnavailableUnavailable31.3%37.3%30.3%
SBC / revenue4.6%4.2%4.4%2.6%3.1%3.2%3.8%2.8%2.8%2.8%
Current ratio1.90x2.35x1.70x1.07x1.91x2.57x2.94x3.06x1.86x1.88x
Revenue YoY growth8.6%8.9%-8.9%15.1%11.4%32.5%-3.9%35.3%40.6%Unavailable
Net margin-5.4%11.2%0.2%9.1%9.2%24.4%28.8%27.1%19.0%42.4%
R&D / revenue14.8%16.4%15.1%11.2%15.6%14.6%17.6%21.8%16.4%19.9%
CapEx / revenue0.2%0.1%0.1%0.1%UnavailableUnavailableUnavailable0.2%0.7%0.7%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailable24.5%52.5%0.1%27.0%24.7%23.3%20.8%43.1%-81.1%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open SUPN in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-03View SEC filing
10-Q · Filed 2026-05-05View SEC filing
10-K · Filed 2026-03-02View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-05View SEC filing
10-Q · Filed 2025-05-06View SEC filing

Companies in the same industry

Reconciliation checks needing review

2 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

gross profit bridgeinconsistent2020-12-31

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2019-12-31

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.